X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-02 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $80.08 | -20,000 | 1,235 | -94% | -$1,601,526 | |||||
| D | 2025-12-01 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $79.52 | -20,000 | 117,896 | -15% | -$1,590,490 | |||||
| D | 2025-12-01 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $79.53 | -5,000 | 10,523 | -32% | -$397,632 | |||||
| DM | 2025-12-02 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale+OE | $30.22 | -4,020 | 15,156 | -21% | -$121,468 | |||||
| DM | 2025-12-02 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. Md | Dir | S - Sale+OE | $30.22 | -2,136 | 51,305 | -4% | -$64,541 | |||||
2025-11-28 | XENE | Xenon Pharmaceuticals Inc. | Mortimer Ian | Pres, CEO | S - Sale | $45.01 | -97 | 45,505 | 0% | -$4,366 | ||||||
| DM | 2025-12-02 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale+OE | $30.22 | -4,576 | 19,612 | -19% | -$138,268 | |||||
2025-12-01 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $79.77 | -40,000 | 2,701,370 | -1% | -$3,190,796 | ||||||
| D | 2025-12-01 | FOLD | Amicus Therapeutics, Inc. | Campbell Bradley L | Pres, CEO | S - Sale+OE | $10.01 | -14,587 | 1,137,282 | -1% | -$146,011 | |||||
| A | 2025-11-25 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale | $80.90 | -4,500 | 787 | -85% | -$364,070 | |||||
| D | 2025-12-01 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Officer | S - Sale+OE | $32.98 | -3,333 | 84,974 | -4% | -$109,929 | |||||
2025-12-01 | IONS | Ionis Pharmaceuticals Inc | Wender Joseph H | Dir | S - Sale | $80.82 | -28,000 | 52,035 | -35% | -$2,262,848 | ||||||
| D | 2025-12-02 | MDGL | Madrigal Pharmaceuticals, Inc. | Dier Mardi | EVP, CFO | S - Sale+OE | $578.34 | -4,173 | 10,440 | -29% | -$2,413,416 | |||||
| M | 2025-12-01 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $37.53 | +6,864 | 380,964 | +2% | +$257,610 | |||||
2025-12-01 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $30.23 | -1,657 | 150,641 | -1% | -$50,091 | ||||||
2025-12-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $30.21 | -10,000 | 79,744 | -11% | -$302,133 | ||||||
2025-12-02 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $79.07 | -3,428 | 349,964 | -1% | -$271,052 | ||||||
2025-12-01 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $39.87 | -69,582 | 690,142 | -9% | -$2,773,956 | ||||||
2025-12-01 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.92 | -41,575 | 227,994 | -15% | -$1,659,489 | ||||||
2025-12-02 | ENTA | Enanta Pharmaceuticals Inc | Capps Kathleen S. | See Remarks | S - Sale | $13.96 | -207 | 8,700 | -2% | -$2,890 | ||||||
2025-12-01 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $195.84 | -467 | 44,121 | -1% | -$91,457 | ||||||
2025-12-02 | ENTA | Enanta Pharmaceuticals Inc | Trout Harry R. III | See Remarks | S - Sale | $13.96 | -380 | 16,890 | -2% | -$5,305 | ||||||
| D | 2025-12-01 | NUVB | Nuvation Bio Inc. | Liu Dongfang | CHIEF MEDICAL OFFICER | S - Sale+OE | $7.82 | -150,000 | 18,000 | -89% | -$1,173,255 | |||||
2025-12-01 | AMLX | Amylyx Pharmaceuticals, Inc. | Bedrosian Camille L | Chief Medical Officer | S - Sale | $14.35 | -6,580 | 175,756 | -4% | -$94,418 | ||||||
2025-12-01 | ANNX | Annexon, Inc. | Choi Jung | Dir | P - Purchase | $4.19 | +33,000 | 33,000 | New | +$138,270 | ||||||
2025-12-01 | ANNX | Annexon, Inc. | Carson William H. | Dir | P - Purchase | $4.47 | +4,115 | 50,290 | +9% | +$18,394 | ||||||
| D | 2025-12-01 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale+OE | $35.01 | -20,000 | 92,083 | -18% | -$700,202 | |||||
| D | 2025-12-01 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Chief Med, Dev Officer | S - Sale+OE | $45.02 | -5,000 | 66,837 | -7% | -$225,100 | |||||
| D | 2025-12-01 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $206.98 | -8,895 | 83,111 | -10% | -$1,841,101 | |||||
2025-12-01 | GNLX | Genelux Corp | Thomas John | Dir | S - Sale | $5.00 | -10,000 | 492,784 | -2% | -$50,008 | ||||||
2025-12-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $7.01 | -16,667 | 1,320,176 | -1% | -$116,781 | ||||||
| D | 2025-12-02 | CYTK | Cytokinetics Inc | Henderson John T | Dir | S - Sale+OE | $63.90 | -8,750 | 74,661 | -10% | -$559,125 | |||||
| D | 2025-12-02 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $63.89 | -2,200 | 140,610 | -2% | -$140,558 | |||||
| M | 2025-11-28 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | SVP Operations | S - Sale | $60.00 | -1,000 | 42,048 | -2% | -$60,000 | |||||
| D | 2025-12-01 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $32.19 | -1,072 | 591,788 | 0% | -$34,508 | |||||
2025-12-01 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale | $32.19 | -221 | 141,218 | 0% | -$7,114 | ||||||
| D | 2025-12-01 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $479.99 | -21,000 | 8,142 | -72% | -$10,079,696 | |||||
| D | 2025-12-01 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $32.19 | -1,166 | 353,823 | 0% | -$37,534 | |||||
| DM | 2025-12-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $481.61 | -8,000 | 644,489 | -1% | -$3,852,846 | |||||
2025-12-01 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale | $32.19 | -303 | 155,031 | 0% | -$9,754 | ||||||
| D | 2025-12-01 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $479.92 | -22,500 | 2,648 | -89% | -$10,798,079 | |||||
| D | 2025-12-01 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $32.19 | -693 | 175,868 | 0% | -$22,308 | |||||
| D | 2025-11-28 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $108.58 | -4,000 | 48,034 | -8% | -$434,319 | |||||
| D | 2025-12-01 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $32.19 | -831 | 154,506 | -1% | -$26,750 | |||||
| M | 2025-11-28 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $42.10 | -7,040 | 43,640 | -14% | -$296,376 | |||||
| M | 2025-11-28 | BMEA | Biomea Fusion, Inc. | Erdtmann Rainer M | See Remarks | P - Purchase | $1.09 | +50,000 | 2,542,820 | +2% | +$54,552 | |||||
| D | 2025-12-01 | MIRM | Mirum Pharmaceuticals, Inc. | Grey Michael G | Dir | S - Sale+OE | $74.00 | -50,000 | 280,160 | -15% | -$3,700,000 | |||||
| D | 2025-12-01 | CYTK | Cytokinetics Inc | Kaye Edward M. Md | Dir | S - Sale+OE | $66.72 | -28,064 | 9,977 | -74% | -$1,872,430 | |||||
2025-12-01 | CYTK | Cytokinetics Inc | Harrington Robert Arthur | Dir | S - Sale | $66.80 | -2,150 | 18,542 | -10% | -$143,620 | ||||||
| D | 2025-11-26 | TBPH | Theravance Biopharma, Inc. | Broshy Eran | Dir | S - Sale+OE | $20.00 | -29,501 | 44,703 | -40% | -$590,020 | |||||
| D | 2025-11-26 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale+OE | $177.81 | -77,500 | 393,332 | -16% | -$13,780,337 | |||||
| M | 2025-11-26 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.96 | -91,088 | 3,196,463 | -3% | -$87,833 | |||||
| M | 2025-11-26 | HOWL | Werewolf Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $0.96 | -141,927 | 4,983,843 | -3% | -$136,855 | |||||
| M | 2025-11-26 | HOWL | Werewolf Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale | $0.96 | -141,927 | 4,983,843 | -3% | -$136,855 | |||||
2025-11-28 | ARWR | Arrowhead Pharmaceuticals, Inc. | Ferrari Mauro | Dir | S - Sale | $56.39 | -8,750 | 68,764 | -11% | -$493,413 | ||||||
| D | 2025-11-26 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Chief Accounting Officer | S - Sale+OE | $26.00 | -1,900 | 27,363 | -6% | -$49,400 | |||||
| M | 2025-11-26 | ALMS | Alumis Inc. | Akkaraju Srinivas | Dir | P - Purchase | $7.55 | +173,589 | 5,308,580 | +3% | +$1,310,677 | |||||
2025-12-01 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale | $29.30 | -4,000 | 65,740 | -6% | -$117,200 | ||||||
| D | 2025-11-26 | ONC | Beone Medicines Ltd. | Sanders Corazon (Corsee) D. | Dir | S - Sale+OE | $340.90 | -2,627 | 57,226 | -4% | -$895,534 | |||||
| M | 2025-11-26 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $10.50 | -6,000 | 426,818 | -1% | -$63,000 | |||||
| D | 2025-11-26 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $42.89 | -200 | 22,714 | -1% | -$8,578 | |||||
| DM | 2025-11-26 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $486.34 | -8,000 | 644,489 | -1% | -$3,890,754 | |||||
| D | 2025-11-26 | RAPP | Rapport Therapeutics, Inc. | Gault Cheryl | COO | S - Sale+OE | $30.10 | -5,000 | 171,928 | -3% | -$150,487 | |||||
2025-11-26 | JNJ | Johnson & Johnson | Morikis John G | Dir | P - Purchase | $206.15 | +1,250 | 1,849 | +209% | +$257,688 | ||||||
2025-11-26 | CVRX | Cvrx, Inc. | Johnson & Johnson | 10% | S - Sale | $10.03 | -6,337 | 4,040,861 | 0% | -$63,560 | ||||||
2025-11-26 | TEVA | Teva Pharmaceutical Industries Ltd | Mignone Roberto | Dir | S - Sale | $26.03 | -50,000 | 550,315 | -8% | -$1,301,505 | ||||||
2025-11-28 | KTTA | Pasithea Therapeutics Corp. | Steinman Lawrence | Dir | P - Purchase | $0.75 | +133,333 | 199,691 | +201% | +$100,000 | ||||||
2025-11-28 | KTTA | Pasithea Therapeutics Corp. | Marques Tiago | CEO | P - Purchase | $0.75 | +33,333 | 73,334 | +83% | +$25,000 | ||||||
2025-11-28 | KTTA | Pasithea Therapeutics Corp. | Dumesnil Simon | Dir | P - Purchase | $0.75 | +33,333 | 35,833 | >999% | +$25,000 | ||||||
| M | 2025-11-28 | MAIA | Maia Biotechnology, Inc. | Vitoc Vlad | CEO, 10% | P - Purchase | $1.11 | +72,000 | 1,063,421 | +7% | +$79,849 | |||||
| M | 2025-11-26 | MAIA | Maia Biotechnology, Inc. | Luput Cristian | Dir | P - Purchase | $1.10 | +38,145 | 437,628 | +10% | +$41,846 | |||||
2025-11-26 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $1.04 | +15,000 | 1,364,289 | +1% | +$15,582 | ||||||
| D | 2025-11-25 | IONS | Ionis Pharmaceuticals Inc | Klein Joseph III | Dir | S - Sale+OE | $80.00 | -12,000 | 16,446 | -42% | -$960,000 | |||||
| D | 2025-11-25 | IONS | Ionis Pharmaceuticals Inc | Devers Shannon L. | EVP, Chief HR Ofc | S - Sale+OE | $80.91 | -16,777 | 17,494 | -49% | -$1,357,442 | |||||
2025-11-25 | BHC | Bausch Health Companies Inc. | Paulson & Co. Inc. | 10% | P - Purchase | $6.25 | +2,500,000 | 73,255,869 | +4% | +$15,625,000 | ||||||
| D | 2025-11-26 | CPRX | Catalyst Pharmaceuticals, Inc. | Del Carmen Jeffrey | Chief Commercial Officer | S - Sale+OE | $23.33 | -10,983 | 3,962 | -73% | -$256,244 | |||||
| D | 2025-11-25 | MRUS | Merus N.V. | Shuman Harry | VP Controller, PAO | S - Sale+OE | $95.92 | -8,300 | 11,002 | -43% | -$796,136 | |||||
2025-11-26 | COCP | Cocrystal Pharma, Inc. | Frost Phillip Md Et Al | Dir, 10% | P - Purchase | $0.99 | +4,000 | 1,730,651 | 0% | +$3,975 | ||||||
2025-11-25 | MAIA | Maia Biotechnology, Inc. | Luput Cristian | Dir | P - Purchase | $0.98 | +10,000 | 399,483 | +3% | +$9,785 | ||||||
2025-11-25 | MAIA | Maia Biotechnology, Inc. | Vitoc Vlad | CEO, 10% | P - Purchase | $0.97 | +10,500 | 1,041,421 | +1% | +$10,144 | ||||||
2025-11-25 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $8.37 | +4,600 | 5,588,102 | 0% | +$38,502 | ||||||
| D | 2025-11-24 | CRMD | Cormedix Inc. | Dillione Janet | Dir | S - Sale+OE | $9.93 | -26,343 | 48,473 | -35% | -$261,586 | |||||
| D | 2025-11-24 | FOLD | Amicus Therapeutics, Inc. | Castelli Jeff | Chief Development Officer | S - Sale+OE | $10.16 | -76,158 | 439,318 | -15% | -$773,659 | |||||
2025-11-24 | FOLD | Amicus Therapeutics, Inc. | Clark David Michael | Chief People Officer | S - Sale | $10.10 | -25,643 | 296,975 | -8% | -$258,933 | ||||||
| D | 2025-11-24 | FOLD | Amicus Therapeutics, Inc. | Campbell Bradley L | Pres, CEO | S - Sale+OE | $10.04 | -14,587 | 1,137,282 | -1% | -$146,522 | |||||
| DM | 2025-11-24 | FOLD | Amicus Therapeutics, Inc. | Rosenberg Ellen | GC | S - Sale+OE | $10.02 | -95,621 | 522,710 | -15% | -$958,478 | |||||
| D | 2025-11-24 | KALV | Kalvista Pharmaceuticals, Inc. | Piekos Brian | CFO | S - Sale+OE | $13.45 | -4,471 | 10,529 | -30% | -$60,139 | |||||
| D | 2025-11-24 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $13.45 | -4,331 | 223,508 | -2% | -$58,256 | |||||
| D | 2025-11-24 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | CHIEF MEDICAL OFFICER | S - Sale+OE | $13.45 | -5,296 | 131,831 | -4% | -$71,236 | |||||
| D | 2025-11-24 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $13.45 | -10,940 | 416,189 | -3% | -$147,154 | |||||
| M | 2025-11-24 | SION | Sionna Therapeutics, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $44.55 | -108,073 | 3,596,886 | -3% | -$4,814,205 | |||||
| M | 2025-11-24 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.55 | -108,073 | 3,596,886 | -3% | -$4,814,205 | |||||
| M | 2025-11-24 | ORGO | Organogenesis Holdings Inc. | Nussdorf Glenn H | Dir, 10% | S - Sale | $5.31 | -300,000 | 11,948,560 | -2% | -$1,592,120 | |||||
| DM | 2025-11-25 | NUVB | Nuvation Bio Inc. | Liu Dongfang | CHIEF MEDICAL OFFICER | S - Sale+OE | $7.75 | -20,000 | 18,000 | -53% | -$155,000 | |||||
| M | 2025-11-25 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $43.97 | -12,320 | 50,680 | -20% | -$541,674 | |||||
| D | 2025-11-25 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale+OE | $83.44 | -71,928 | 106,804 | -40% | -$6,001,932 | |||||
2025-11-25 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale | $80.90 | -4,500 | 787 | -85% | -$364,070 | ||||||
| D | 2025-11-25 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.90 | -5,965 | 5,965 | -50% | -$23,264 | |||||
| D | 2025-11-24 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale+OE | $80.18 | -35,572 | 106,804 | -25% | -$2,852,031 | |||||
| DM | 2025-11-24 | PTCT | Ptc Therapeutics, Inc. | Jacobson Allan Steven | Dir | S - Sale+OE | $82.00 | -26,000 | 17,451 | -60% | -$2,132,018 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |